POSTGRADUATE RESEARCH INSTITUTE cyprushost
 
 
  About PRI
  Research at PRI
  Publications
  Deferiprone
  ICOC Conference
  RAHMS Conference
  Donations
  Contact PRI

Several PRI studies have been published in a number of international journals including:

ArzneimForschDrugRes

Biomarkers and Environment
 
Drugs of Today

Journal of Radioanalytical and Nuclear Chemistry

Lancet
 
SOSTE Notiziario

Transfusion Science



 
 
Publications

The main topics of research and publications thus far has been the pioneering discovery by G.J. Kontoghiorghes of the new iron chelating drug Deferiprone (L1), which is used worldwide in thalassaemia, cancer, leukaemia, haemodialysis and other patients. Deferiprone has been licensed in many countries and in Europe since August 1999. It is currently used in thousands of patients worldwide. It is worth noting that the drug Deferiprone may be used in the detoxification of other metals such as aluminium in haemodialysis patients, plutonium used in the nuclear industry, and uranium used by the military. 

Access to publications

Maher P, Kontoghiorghes GJ. (2015)
Characterization of the Neuroprotective Potential of Derivatives of the Iron Chelating Drug
Neurochemical Research 2015;40:609-620

Timoshnikov VA, Kobzeva TV, Polyakov NE, Kontoghiorghes GJ. (2015)
Inhibition of Fe(2+)- and Fe(3+)- induced hydroxyl radical production by the iron-chelating drug deferiprone.
Free Radicals Biology and Medicine 78:118-122.

Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ. (2014)
Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.
World Journal of Methodology 4:197-218

Timoshnikov VA, Klimentiev VI, Polyakov NE, Kontoghiorghes GJ (2014)
Photoinduced transformation of iron chelator deferiprone: Possible implications in drug metabolism and toxicity.
Journal of Photochemistry and Photobiology A: Chemistry 289:14-21

Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. (2014)
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.
World Journal of Methodology 4:163-188

Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ. (2014)
Antioxidant targeting by deferiprone in diseases related to oxidative damage.
Frontiers Bioscience (Landmark Ed). 19:862-85.

Kontoghiorghes G J (2013)
Turning a blind eye to deferasirox's toxicity?
Lancet 381 (9873): 1183-1184

Kontoghiorghes G J (2013)
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
Expert Opin Drug Saf. 2013;12:605-609

Kontoghiorghes G J (2013)
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Author's response.
Expert Opin Drug Saf. 2013;12: 794-795

Kontoghiorghes GJ. (2013)
The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies.
Toxicol Mech Methods. 23 (1) :1-4.

Kolnagou A, Natsiopoulos K, Kleanthous M, Ioannou A, Kontoghiorghes GJ. (2013)
Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
Toxicol Mech Methods. 23(1):48-56.

Born T, Kontoghiorghe CN, Spyrou A, Kolnagou A, Kontoghiorghes GJ. (2013)
EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment.
Toxicol Mech Methods. 23(1):11-17.

Kolnagou A, Michaelides Y, Kontoghiorghe CN, Kontoghiorghes GJ. (2013)
The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients.
Toxicol Mech Methods. 23(1):34-41


Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ (2013)
Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.
Expert Opin Investig Drugs. 22:591-618

Flaten TP, Aaseth J, Andersen O, Kontoghiorghes GJ. (2012)
Iron mobilization using chelation and phlebotomy.
J Trace Elem Med Biol. 26 (2-3):127-130.

Kontoghiorghes GJ. (2011)
The proceedings of the 19th international conference on chelation held in London, United Kingdom: major changes in iron chelation therapy in the last 25 years using deferiprone (L1) has resulted in the complete treatment of iron overload.
Hemoglobin. 35(3):181-185.

Kolnagou A, Kleanthous M, Kontoghiorghes GJ. (2011)
Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
Hemoglobin. 35(3):186-198.

Konstantinou E, Pashalidis I, Kolnagou A, Kontoghiorghes GJ. (2011)
Interactions of hydroxycarbamide (hydroxyurea) with iron and copper: implications on toxicity and therapeutic strategies.
Hemoglobin. 35(3):237-246.

Kontoghiorghes GJ. (2011)
A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients.
Hemoglobin. 35(3):301-311.

Kolnagou A, Kontoghiorghes GJ (2010)
New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores.
Br J Haematol.2010 150(4):489-90.

Kolnagou A, Kontoghiorghes GJ (2010)
Future challenges in the use of magnetic resonance imaging for the diagnosis of iron overload.
Blood Transfusion 8(4):309-10.

Kolnagou A, Kleanthous M, Kontoghiorghes GJ (2010)
Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Eur J Haematol. 85(5):430-8

Kontoghiorghes GJ (2010)
Introduction of higher doses of deferasirox: Better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Expert Opinion in Drug Safety 9(4):633-641.

Kontoghiorghes GJ (2010)
The 18th ICOC proceedings in Athens, Greece: new breakthrough in thalassemia leading to the complete treatment of iron overload and to hundreds of patients achieving and maintaining normal body iron stores. Ethical questions on chelation therapy.
Hemoglobin. 34(3):199-203

Kontoghiorghes G J, Spyrou A, Kolnagou A (2010)
Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
Hemoglobin. 34(3):251-264

Kontoghiorghes G J, Kolnagou A, Skiada A, Petrikkos G (2010)
The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
Hemoglobin. 34(3):227-239

Kolnagou A, Kontoghiorghes GJ (2010)
Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
Hemoglobin. 34(3):204-209.

Kontoghiorghes GJ, Kolnagou A, Peng CT, Shah SV, Aessopos A (2010).
Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.
Expert Opinion on Drug Safety 9(2):201-6.

Kontoghiorghes GJ (2009)
The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
Hemoglobin 33 (5):283-6.

Kolnagou A, Kontoghiorghes GJ (2009)
Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
Hemoglobin. 33(5):287-95.

Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ (2009).
Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Hemoglobin. 33(5):312-22

Kontoghiorghes GJ (2009)
A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Hemoglobin. 33(5):332-8

Kontoghiorghes GJ, Efstathiou A, Kleanthous M, Michaelides Y, Kolnagou A (2009).
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Hemoglobin. 33(5):386-97.

Kontoghiorghes G J.
Prospects for introducing deferiprone as potent pharmaceutical antioxidant.
Frontiers Bioscience 2009; E1: 161-78.

Kontoghiorghes G J.
Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.
Expert Opinion Drug Safety 2008; 7(6):1-2.

Kontoghiorghes G J.
Transparency and Access to Full Information for the Fatal or Serious Toxicity Risks, Low Efficacy and High Price of Deferasirox, Could Increase the Prospect of Improved Iron Chelation Therapy Worldwide.
Hemoglobin 2008; 32: 608 - 615.

Kontoghiorghes GJ, Efstathiou A, Ioannou-Loucaides S, Kolnagou A.
Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.
Hemoglobin. 2008;32:217-227.

Fukuda S, Ikeda M, Nakamura M, Katoh A, Yan X, Xie Y, Kontoghiorghes GJ.
The effects of bicarbonate and its combination with chelating agents used for the removal of depleted uranium in rats.
Hemoglobin. 2008;32:191-198.

Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Hemoglobin. 2008;32:41-47.

Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ.
Myocyte Damage and Loss of Myofibers is the Potential Mechanism of Iron Overload Toxicity in Congestive Cardiac Failure in Thalassemia. Complete Reversal of the Cardiomyopathy and Normalization of Iron Load by Deferiprone.
Hemoglobin. 2008;32:17-28.

Kontoghiorghes GJ.
Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/Deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox.
Hemoglobin. 2008;32:1-15.

Kontoghiorghes G J.
Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities.
Expert Opin. Drug Saf. (2007) 6(3):235-239.

Kontoghiorghes G J, Kolnagou A.
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Haematologica 2006; 91:(ELT) 04.

Kontoghiorghes G J.
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Hemoglobin 2006; 30:329-347.

Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes G J.
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. the importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Hemoglobin 2006; 30: 219-227.

Kolnagou A, Kontoghiorghes G J.

Effective combination therapy of deferiprone and desferrioxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. the protocol of the international committee on oral chelators.
Hemoglobin 2006; 30: 239-249.

Kontoghiorghes G J.
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Hemoglobin 2006;30:183-200.

Fukuda S, Ikeda M, Anzai K, Suzuki M, Katoh A, Kontoghiorghes G J.
Radiation protection by deferiprone in animal models.
Hemoglobin 2006; 30: 201-208.

Kontoghiorghes GJ.
New chelation therapies and emerging chelating drugs for the treatment of iron overload.
Expert Opin Emer Drugs. 2006; 11: 1-5.

Peng CT, Fucharoen S, Kontoghiorghes GJ, Tsai CH.
Report on the Proceedings of the 15(th) International Conference on Oral Chelation (ICOC) in the Treatmentof Thalassemia and Other Diseases at Taichung, Taiwan, April 22-26, 2005.
Hemoglobin. 2006; 30: 63-68.

Kontoghiorghes GJ.
Effects of ICL670 (deferasirox) on cardiac iron concentrations.
Lancet. 2005; 366:804.

Kontoghiorghes GJ, Kolnagou A, Eracleous E, Evans RW.
Iron mobilisation from transferrin by deferiprone (L1).
Br J Haematol. 2005; 129:157

Kontoghiorghes GJ.
New oral iron-chelating drugs for the treatment of transfusional iron overload and other diseases.
Drugs Future. 2005; 30: 1241-51.

Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A.
Advances in iron overload therapies. Prospects for effective use of deferiprone(L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations.
Curr Med Chem. 2005; 12: 2663-81.

Kontoghiorghes GJ, Kolnagou A.
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators.
Curr Med Chem. 2005; 12: 2695-710.

Kontoghiorghes GJ.
Regulatory molecules and chelators used for the control of essential and toxic metals in health and disease: From molecular interactions to clinical effects and applications.
Curr Med Chem. 2005; 12: 2661-2.

Kolnagou A, Fessas Ch, Papatryphonas A, Economides Ch, Kontoghiorghes GJ.
Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia.
Brit J Haematol. 2004; 127:360-1.

Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A.
The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
Curr Med Chem. 2004;11:2161-83

Kontoghiorghes GJ.
Do we need more iron chelating drugs.
Lancet. 2003; 362: 495-6.

Kontoghiorghes GJ, Neocleous K, Kolnagou A.

Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions. Comparison of epidemiological and therapeutic aspects with deferoxamine.
Drug Saf.  2003; 26: 553-84.

Kontoghiorghes GJ, Kolnagou A.
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Lancet. 2003; 361:184.

Douvas GS, May MH, Kolnagou A, Kontoghiorghes G J.
Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity.
Arzneimittelforschung. 2002;52:45-52.

Kontoghiorghes GJ.
Clinical use, therapeutic aspects and future potential of deferiprone in thalassemia and other conditions of iron and other metal toxicity.
Drugs Today (Barc). 2001 ;37:23-35.

Pashalidis I and Kontoghiorghes GJ.
Molecular factors affecting the complex formation between deferiprone (L1) and Cu(II).
Arzneimittel-Forschung / Drug Research 2001, Volume 51 (II), pages 998-1003

Kontoghiorghes GJ.
Clinical use, therapeutic aspects and future potential of deferiprone in thalassaemia and other conditions of iron and other metal toxicity.
Drugs of Today 2001, Volume 37, pages 23-35

Pashalidis I and Kontoghiorghes GJ.
Interaction of L1-Deferiprone with Cu(II) and U(VI) ions. Chemical characterisation of solid phases and possible clinical application.
Biomarkers and Environment 2001, Volume 4 (suppl 1), pages 80-81

Kontoghiorghes GJ, Sitarou M, Pattichi K and Kolnagou A.
Iron overload toxicity and new therapeutic strategies with the orally effective chelating drug deferiprone (L1).
Biomarkers and Environment 2001, Volume 4 (suppl 1), pages 16-21

Kontoghiorghes GJ, Agarwal MB, Grady RW, Tondury P and Marx JJ.
Deferiprone or fatal iron toxic effects?.
Lancet 2001, Volume 357, pages 882-883.

Kontoghiorghes GJ, Sitarou M, Pattichis K, Hadjigavriel M and Kolnagou A.
Present status and future prospects of oral chelation with L1-deferiprone and other orally active chelators.
SO.S.T.E. Notiziario 2001, Volume 2 (1), pages 98-101

Kontoghiorghes GJ, Agarwal MB, Grady RW, Kolnagou A and Marx JJ.
Deferiprone for thalassaemia.
Lancet 2000, Volume 356, pages 428-429.

Pashalidis I and Kontoghiorghes GJ.
Competition studies of L1-deferiprone with copper and iron. Possible implications on efficacy, toxicity and new therapeutic applications.
Transfusion Science 2000, Volume 23, pages 259-261.

Kontoghiorghes GJ, Pattichi K, Hadjigavriel M and Kolnagou A.
Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Transfusion Science 2000, Volume 23, pages 211-223.

Paschalidis I and Kontoghiorghes GJ.
Effective complex formation in the interaction of 1,2-dimethyl-3-hydroxypyrid-4-one (Deferiprone or L1) with uranium(VI).
Journal of Radioanalytical and Nuclear Chemistry 1999, Volume 242, pages 181-184.

Eybl V, Kotyzova D, Koutensky J, Migkova V, Sykora J and Kontoghiorghes GJ.
The influence of deferiprone (L1) and deferoxamine on the level of essential elements in mice.
Biomarkers and Environment 1999, Volume 3, pages 25-28.

   
Other publications by PRI members

George J Kontoghiorghes
Christina N Kontoghiorghe
Katerina Pattichis
Annita Kolnagou
Eleni Eracleous
Aglaia Efstathiou
Charalambos Economides
Charis Fessas
Stella Ioannou - Loucaides

 

 

 
 

Best viewed with
Internet Explorer
at 800 x 600 or higher
Last update:
24 January 2006

 
 
POSTGRADUATE RESEARCH INSTITUTE Science, Technology, Environment and Medicine
3 Ammochostou Street, CY-3021 Limassol, Cyprus
Postal address: P.O. Box 51342, CY-3504 Limassol, Cyprus
Tel: +357 25 734 615, Fax: +357 25 395 926, Email:
kontoghiorghes.g.j@pri.ac.cy
About PRIResearch at PRI  |  Publications  |  Deferiprone  |  Conferences  |  Sponsors  |  Contact PRI
 
  Copyright © 2002-2006 Postgraduate Research Institute

cyprushost

Designed by LabWell Research Laboratories